Fermer le menu


Member of Lyonbiopole


CYTOO is a drug discovery biotech company focusing on disorders affecting muscle health. CYTOO pioneered MyoScreen™, an in vitro R&D platform that enables testing muscle therapies in primary patient-derived skeletal muscle cells. Using innovative, image-based, high-throughput assays and quantitative functional assays, MyoScreen aids therapeutic discovery at all stages, from target identification to the development of clinical candidate potency assays. Through R&D partnerships, CYTOO has worked on more than 50 projects comprising RNA and gene therapies. To better support CMC related activities, CYTOO is establishing a GMP environment that will be operational in 2023.



Strategic application domain: Medical Technologies

Application market: Ageing, Genetic Disorders, Rare disease

Type of activity: CRO - Tools - R&D platform, Technology provider, Therapeutics, Pharma or Biotech

Technologies: AI, Gene Therapy, Screening methods or services

Created on june 1st, 2008 - 32 employees



7 parvis Louis Néel 38040 Grenoble



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.